« Return to News | Drug Sponsors

GSK to sell OTC brands

Friday, April 15, 2011 12:30 PM

Reorganization of GlaxoSmithKline's consumer healthcare business will result in the divestment of $800 million worth of over-the-counter products, including its controversial weight loss drug Alli, according to Pharma Times.

The move allows GSK to concentrate on a portfolio of "fast-growing priority brands and the emerging markets" within the division. The divested products are primarily sold in Europe and the U.S. and make up 10% of the company’s total consumer healthcare turnover.

Analgesics such as Solpadeine, the vitamin and supplement product Abtei, the ulcer treatment Zantac (ranitidine) OTC and Alli (orlistat) are some that will be divested.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.